PT - JOURNAL ARTICLE AU - Dong Il Won AU - Jihea Park AU - Beom Soo Kim AU - Chae Eun Kim AU - Heon Sik Yoon AU - Ji Soo Jung TI - Neutrophil nuclear patterns to distinguish between pathological and non-pathological autoantibodies detected on HEp-2 cells AID - 10.1101/2020.06.13.20130039 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.13.20130039 4099 - http://medrxiv.org/content/early/2020/06/27/2020.06.13.20130039.short 4100 - http://medrxiv.org/content/early/2020/06/27/2020.06.13.20130039.full AB - Background Antinuclear antibody (ANA) testing is used to diagnose systemic autoimmune rheumatic disease (SARD). Autoantibodies (Abs) associated with the “homogeneous-like” pattern on ANA HEp-2 cell nuclei can be classified as pathological (e.g., anti-dsDNA, anti-nucleosome, anti-histone, anti-Scl-70 Abs) or non-pathological (e.g., anti-DFS70 Abs).Methods Anti-neutrophil cytoplasmic anti-antibody (ANCA) testing was used to classify individuals who presented with a homogeneous-like pattern on ANA testing. Enrolled subjects included (1) young individuals with a dense fine speckled pattern on ANA testing (young non-SARD group, n = 62) and patients with (2) systemic lupus erythematosus (SLE) with anti-dsDNA Abs (SLE group, n = 33), (3) rheumatoid arthritis (RA) with anti-nucleosome, anti-histone Abs, and others (RA group, n = 45), and (4) diffuse systemic sclerosis (SSc) with Scl-70 Abs (diffuse SSc group, n = 11).Results Negative rates (95% confidence interval) of neutrophil nuclear patterns on ANCA testing were: 96.8% (88.8%–99.6%) of the young non-SARD group, 3.0% (0.1 %–15.8%) of the SLE group, 4.4% (0.5%–15.2%) of the RA group, and 54.5% (23.4%–83.3%) of the diffuse SSc group. The negative rate of the non-SARD group was significantly higher than those of the SARD group (all P < 0.05).Conclusions ANCA testing helps to identify individuals with non-pathological anti-DFS70 Abs who present with homogeneous-like patterns in HEp-2 cell nuclei on ANA testing.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was done retrospectively without a clinical trial ID. The study protocol was determined to be exempt by the Institutional Review Board of our hospital (IRB file No.: KNUH 2020-01-051).Funding Statementno fundsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was determined to be exempt by the Institutional Review Board of Kyungpook National University Hospital (Daegu, Korea) (IRB file No.: KNUH 2020-01-051).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes.